Cargando…

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis

BACKGROUND AND OBJECTIVES: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia, Alexandra, Dugast, Emilie, Shah, Sita, Morille, Jérémy, Lebrun-Frenay, Christine, Thouvenot, Eric, De Sèze, Jérôme, Le Page, Emmanuelle, Vukusic, Sandra, Maurousset, Aude, Berger, Eric, Casez, Olivier, Labauge, Pierre, Ruet, Aurélie, Raposo, Catarina, Bakdache, Fabien, Buffels, Régine, Le Frère, Fabienne, Nicot, Arnaud, Wiertlewski, Sandrine, Gourraud, Pierre-Antoine, Berthelot, Laureline, Laplaud, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944617/ https://www.ncbi.nlm.nih.gov/pubmed/36810163 http://dx.doi.org/10.1212/NXI.0000000000200091

Ejemplares similares

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation
por: Nicot, Arnaud B, et al.
Publicado: (2023)

Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature
por: Morille, Jérémy, et al.
Publicado: (2022)

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)

Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
por: Wilson, Sarah, et al.
Publicado: (2022)

Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS
por: Vallino, Amélie, et al.
Publicado: (2020)

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
por: Lebrun-Frénay, Christine, et al.
Publicado: (2021)

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Single-Cell Analysis to Better Understand the Mechanisms Involved in MS
por: Dugast, Emilie, et al.
Publicado: (2022)

Distribution of Bacterial α1,3-Galactosyltransferase Genes in the Human Gut Microbiome
por: Montassier, Emmanuel, et al.
Publicado: (2020)

Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
por: Levraut, Michael, et al.
Publicado: (2022)

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells
por: Tilly, Gaëlle, et al.
Publicado: (2021)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
por: de Sèze, Jérôme, et al.
Publicado: (2023)

DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
por: Sormani, Maria Pia, et al.
Publicado: (2021)

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
por: Tourbah, Ayman, et al.
Publicado: (2018)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Natalizumab alters the TCR repertoire after one year of treatment in four MS patients
por: Michel, Laure, et al.
Publicado: (2011)

Inflammatory-like presentation of CADASIL: a diagnostic challenge
por: Collongues, Nicolas, et al.
Publicado: (2012)

Ocrelizumab-Induced Severe Colitis
por: Lee, Hsing Hwa, et al.
Publicado: (2020)

Covid-19, the pandemic war: Implication for neurologists
por: de Seze, J., et al.
Publicado: (2020)

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
por: Hartung, H-P, et al.
Publicado: (2020)

Semi‐supervised clustering of quaternion time series: Application to gait analysis in multiple sclerosis using motion sensor data
por: Drouin, Pierre, et al.
Publicado: (2022)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
por: Brochet, Bruno, et al.
Publicado: (2017)

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2019)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gm4i7hgkgqfh4hqjhspbod4ucn